A Nashville Startup Just Raised $7.5M to Build the Back Office That Cash-Pay Clinics Don't Have

If you run a DPC practice, you already know the feeling. You’ve built a clinic that works for patients. You’ve freed yourself from insurance billing. But when it comes to prescribing, ordering from compounding pharmacies, and tracking fulfillment, you’re back to faxing, calling, and hoping the order doesn’t get lost.

A Nashville startup called VITL just raised $7.5 million to fix that. And the fact that venture capital is flowing into the infrastructure layer of cash-pay healthcare tells you something about where this market is headed.

What VITL Actually Does

VITL is building what it calls an “operating system for cash-pay health.” In practice, it’s an e-prescribing marketplace that connects clinics with verified 503A and 503B compounding pharmacies nationwide.

Think of it as a single dashboard where a cash-pay clinician can compare prices across multiple compounding pharmacies in real time, place orders, and track a prescription from the moment it’s written to the moment it arrives at a patient’s door. One interface, multiple pharmacy relationships, full visibility.

The company was founded in 2024 and already serves more than 630 clinics and 1,000 prescribers across the country. Its target customers include DPC practices, concierge medicine providers, med spas, hormone clinics, and longevity practices. The common thread is clinics operating outside traditional insurance networks that need prescribing infrastructure the legacy system was never built to serve.

Why SignalFire Wrote the Check

The $7.5 million Series A was led by SignalFire, a data-driven venture firm that reportedly found VITL through its sourcing platform and reached out directly. No pitch deck required.

The investment thesis isn’t hard to see. The cash-pay healthcare market is estimated at roughly $100 billion, and the global DPC market alone reached approximately $61 billion in 2024 with projections near $93 billion by 2034. Patients are leaving the traditional system. DPC, concierge medicine, and cash-pay clinics are all growing at double digits. But the tools supporting those clinics haven’t kept up.

The GLP-1 boom has accelerated this gap. Cash-pay clinics prescribing compounded semaglutide and similar treatments need pharmacy relationships, price transparency, and compliance workflows that the traditional e-prescribing rails weren’t designed to handle. VITL stepped into that gap.

The Infrastructure Story Behind the Funding Story

Here’s why this matters beyond one company’s Series A.

For years, the DPC conversation has focused on the front of the house. Can you get enough members? Can you make the economics work? Can you build a practice that lets you do medicine the way you trained to do it? Those are still the right questions. But they assume the back office will figure itself out.

It hasn’t. Many DPC and cash-pay practices still manage compounding pharmacy relationships through phone calls and fax machines. Price comparison across pharmacies requires manual outreach. Tracking whether a patient’s medication actually shipped means logging into a separate portal or waiting for a confirmation email.

This is the same pattern that plays out across DPC infrastructure. Practices cobble together billing tools, EHR systems, messaging platforms, and scheduling software because no single system was built for how they operate. VITL is addressing one slice of that problem: the prescribing and fulfillment workflow for compounding medications.

The fact that venture capital is funding this infrastructure layer is a signal. When investors start backing the picks-and-shovels companies in a market, it usually means the market itself has crossed a credibility threshold. Investors aren’t betting on whether cash-pay healthcare will grow. They’re betting on which tools will power that growth.

What This Means

If you’re running a DPC practice that works with compounding pharmacies, VITL might be worth watching. A platform that lets you compare prices and manage orders from one place could save real time and money on the prescribing side of your practice. That said, the company is still early, and it’s worth evaluating how deeply it integrates with the rest of your workflow before adding another tool to the stack.

For physicians considering the DPC model, this funding round is a data point in a larger trend. The ecosystem supporting cash-pay and DPC practices is getting more sophisticated. Two years ago, you might have worried about building a practice on infrastructure that didn’t exist yet. Today, companies are raising millions specifically to build the tools you’ll need.

The broader picture is that DPC is no longer a niche experiment that venture capital ignores. The infrastructure layer is filling in. That doesn’t mean every startup in this space will survive. But it does mean the market has matured enough that serious investors are placing bets on its future. For anyone building or considering a DPC practice, that’s a signal worth paying attention to.